JP2023554354A - アルツハイマー病の処置のためのマシチニブ - Google Patents

アルツハイマー病の処置のためのマシチニブ Download PDF

Info

Publication number
JP2023554354A
JP2023554354A JP2023536086A JP2023536086A JP2023554354A JP 2023554354 A JP2023554354 A JP 2023554354A JP 2023536086 A JP2023536086 A JP 2023536086A JP 2023536086 A JP2023536086 A JP 2023536086A JP 2023554354 A JP2023554354 A JP 2023554354A
Authority
JP
Japan
Prior art keywords
masitinib
pharmaceutically acceptable
score
acceptable salt
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023536086A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554354A5 (https=
Inventor
マウジー，アレン
マンスフィールド，コリン
Original Assignee
エービー サイエンス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エービー サイエンス filed Critical エービー サイエンス
Publication of JP2023554354A publication Critical patent/JP2023554354A/ja
Publication of JP2023554354A5 publication Critical patent/JP2023554354A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023536086A 2020-12-16 2021-12-16 アルツハイマー病の処置のためのマシチニブ Pending JP2023554354A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20306589 2020-12-16
EP20306589.1 2020-12-16
PCT/EP2021/086308 WO2022129410A1 (en) 2020-12-16 2021-12-16 Masitinib for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2023554354A true JP2023554354A (ja) 2023-12-27
JP2023554354A5 JP2023554354A5 (https=) 2024-12-23

Family

ID=74141317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023536086A Pending JP2023554354A (ja) 2020-12-16 2021-12-16 アルツハイマー病の処置のためのマシチニブ

Country Status (10)

Country Link
US (1) US20240058328A1 (https=)
EP (1) EP4262801A1 (https=)
JP (1) JP2023554354A (https=)
KR (1) KR20230125804A (https=)
CN (1) CN116963736A (https=)
AU (1) AU2021399925A1 (https=)
CA (1) CA3201259A1 (https=)
IL (1) IL303521A (https=)
MX (1) MX2023007029A (https=)
WO (1) WO2022129410A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025113494A1 (zh) * 2023-11-27 2025-06-05 浙江径科医药有限公司 多环类化合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011110608A1 (en) * 2010-03-09 2011-09-15 Ab Science Treatment of dementia of alzheimer's type with masitinib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05001277A (es) 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
US8153792B2 (en) 2007-02-13 2012-04-10 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011110608A1 (en) * 2010-03-09 2011-09-15 Ab Science Treatment of dementia of alzheimer's type with masitinib

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Record History: NCT00976118, Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease", CLINICALTRIALS.GOV ARCHIVE [ONLINE], vol. [retrieved on 20251006], JPN6025041906, 12 December 2018 (2018-12-12), ISSN: 0005707685 *
ALZHEIMER'S RESEARCH & THERAPY, vol. 3, JPN6025041908, 2011, pages 16, ISSN: 0005707684 *
EXPERT REVIEW OF NEUROTHERAPEUTICS, vol. 15, no. 6, JPN6025041907, 2015, pages 587 - 596, ISSN: 0005707686 *

Also Published As

Publication number Publication date
EP4262801A1 (en) 2023-10-25
KR20230125804A (ko) 2023-08-29
IL303521A (en) 2023-08-01
WO2022129410A1 (en) 2022-06-23
CN116963736A (zh) 2023-10-27
AU2021399925A1 (en) 2023-06-29
CA3201259A1 (en) 2022-06-23
MX2023007029A (es) 2023-07-18
US20240058328A1 (en) 2024-02-22
AU2021399925A9 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
JP7080944B2 (ja) 細胞生存率を向上させるための組成物およびその使用方法
US9855276B2 (en) Combination therapies for the treatment of Alzheimer's disease and related disorders
KR102559354B1 (ko) 치매 치료
JP7731868B2 (ja) ＴＤＰ－４３、α－シヌクレイン、ハンチンチンタンパク質及びタウタンパク質のオリゴマー形成に関連する疾患を治療するための小分子薬物、並びに関連する方法
US20180311236A1 (en) Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease
JP7788154B2 (ja) 多発性硬化症患者の亜集団の処置のためのマシチニブ
JP2023554354A (ja) アルツハイマー病の処置のためのマシチニブ
JP2006516629A (ja) 置換キノリンおよび置換ジフェニルスルホンを含有する組成物および方法
JP2006522050A (ja) 認知症患者における激越の処置のためのカルバマゼピン誘導体の使用
HK1213494B (en) Combination therapies for the treatment of alzheimer's disease and related disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251014

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260414